|
1
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Han L, Xu G, Xu C, Liu B and Liu D:
Potential prognostic biomarkers identified by DNA methylation
profiling analysis for patients with lung adenocarcinoma. Oncol
Lett. 15:3552–3557. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zarogoulidis P, Petanidis S, Kioseoglou E,
Domvri K, Anestakis D and Zarogoulidis K: MiR-205 and miR-218
expression is associated with carboplatin chemoresistance and
regulation of apoptosis via Mcl-1 and survivin in lung cancer
cells. Cell Signal. 27:1576–1588. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tian H, Liu S, Zhang J, Zhang S, Cheng L,
Li C, Zhang X, Dail L, Fan P, Dai L, et al: Enhancement of
cisplatin sensitivity in lung cancer xenografts by
liposome-mediated delivery of the plasmid expressing small hairpin
RNA targeting survivin. J Biomed Nanotechnol. 8:633–641.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang Y, Yuan Y, Li Y, Zhang P, Chen P and
Sun S: An inverse interaction between HOXA11 and HOXA11-AS is
associated with cisplatin resistance in lung adenocarcinoma.
Epigenetics. 14:949–960. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li J, Wang Y, Song Y, Fu Z and Yu W:
MiR-27a regulates cisplatin resistance and metastasis by targeting
RKIP in human lung adenocarcinoma cells. Mol Cancer.
13(193)2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhan J, Wang P, Li S, Song J, He H, Wang
Y, Liu Z, Wang F, Bai H, Fang W, et al: HOXB13 networking with
ABCG1/EZH2/Slug mediates metastasis and confers resistance to
cisplatin in lung adenocarcinoma patients. Theranostics.
9:2084–2099. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344.
2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Lathia J, Liu H and Matei D: The clinical
impact of cancer stem cells. Oncologist. 17(0517)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bora-Singhal N, Mohankumar D, Saha B,
Colin CM, Lee JY, Martin MW, Zheng X, Coppola D and Chellappan S:
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell
self-renewal and overcome drug resistance by suppressing Sox2. Sci
Rep. 10(4722)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu CH, Yeh DW, Lai CY, Liu YL, Huang LR,
Lee AY, Jin SC and Chuang TH: USP17 mediates macrophage-promoted
inflammation and stemness in lung cancer cells by regulating
TRAF2/TRAF3 complex formation. Oncogene. 37:6327–6340.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of oct4 and nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: The cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Takebe N, Miele L, Harris PJ, Jeong W,
Bando H, Kahn M, Yang SX and Ivy SP: Targeting notch, hedgehog, and
Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin
Oncol. 12:445–464. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chatterjee S and Sil PC: Targeting the
crosstalks of Wnt pathway with hedgehog and notch for cancer
therapy. Pharmacol Res. 142:251–261. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Park EY, Chang E, Lee EJ, Lee HW, Kang HG,
Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of
miR34a-NOTCH1 axis reduced breast cancer stemness and
chemoresistance. Cancer Res. 74:7573–7582. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the
self-renewal, tumorigenicity, and chemoresistance of colorectal
cancer stem cells. Stem Cells. 29:1661–1671. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Wang X, Meng Q, Qiao W, Ma R, Ju W, Hu J,
Lu H, Cui J, Jin Z, Zhao Y and Wang Y: MiR-181b/Notch2 overcome
chemoresistance by regulating cancer stem cell-like properties in
NSCLC. Stem Cell Res Ther. 9(327)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu T, Wu X, Chen T, Luo Z and Hu X:
Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem
cell-like phenotypes through repressing Wnt/β-catenin signaling.
Clin Cancer Res. 24:1748–1760. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Sun T, Song Y, Yu H and Luo X:
Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's
proliferates and anti-apoptotic effect on breast cancer using
co-expression network analysis. Cancer Biol Ther. 20:760–773.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang QY, Men CJ and Ding XW: Upregulation
of microRNA-140-3p inhibits epithelial-mesenchymal transition,
invasion, and metastasis of hepatocellular carcinoma through
inactivation of the MAPK signaling pathway by targeting GRN. J Cell
Biochem. 120:14885–14898. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou Y, Wang B, Wang Y, Chen G, Lian Q and
Wang H: MiR-140-3p inhibits breast cancer proliferation and
migration by directly regulating the expression of tripartite motif
28. Oncol Lett. 17:3835–3841. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li J, Zhao J, Wang H, Li X, Liu A, Qin Q
and Li B: MicroRNA-140-3p enhances the sensitivity of
hepatocellular carcinoma cells to sorafenib by targeting
pregnenolone X receptor. Onco Targets Ther. 11:5885–5894.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Huang H, Wang Y, Li Q, Fei X, Ma H and Hu
R: MiR-140-3p functions as a tumor suppressor in squamous cell lung
cancer by regulating BRD9. Cancer Lett. 446:81–89. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cao S, Wang Z, Gao X, He W, Cai Y, Chen H
and Xu R: FOXC1 induces cancer stem cell-like properties through
upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res.
37(220)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cui Y, Ma W, Lei F, Li Q, Su Y, Lin X, Lin
C, Zhang X, Ye L, Wu S, et al: Prostate tumour overexpressed-1
promotes tumourigenicity in human breast cancer via activation of
Wnt/β-catenin signalling. J Pathol. 239:297–308. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root
of resistance. Cancer Lett. 372:147–156. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jiang N, Zou C, Zhu Y, Luo Y, Chen L, Lei
Y, Tang K, Sun Y, Zhang W, Li S, et al: HIF-1a-regulated miR-1275
maintains stem cell-like phenotypes and promotes the progression of
LUAD by simultaneously activating Wnt/β-catenin and notch
signaling. Theranostics. 10:2553–2570. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li T, Ding ZL, Zheng YL and Wang W:
MiR-484 promotes non-small-cell lung cancer (NSCLC) progression
through inhibiting apaf-1 associated with the suppression of
apoptosis. Biomed Pharmacother. 96:153–164. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ma Z, Cai H, Zhang Y, Chang L and Cui Y:
MiR-129-5p inhibits non-small cell lung cancer cell stemness and
chemoresistance through targeting DLK1. Biochem Biophys Res Commun.
490:309–316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang Y, Du H, Li Y, Yuan Y, Chen B and
Sun S: Elevated TRIM23 expression predicts cisplatin resistance in
lung adenocarcinoma. Cancer Sci. 111:637–646. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chen MJ, Wu DW, Wang YC, Chen CY and Lee
H: PAK1 confers chemoresistance and poor outcome in non-small cell
lung cancer via beta-catenin-mediated stemness. Sci Rep.
6(34933)2016.
|
|
42
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: BBI608 inhibits cancer stemness
and reverses cisplatin resistance in NSCLC. Cancer Lett.
428:117–126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lathia JD and Liu H: Overview of cancer
stem cells and stemness for community oncologists. Targeted Oncol.
12:387–399. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Najafi M, Farhood B and Mortezaee K:
Cancer stem cells (CSCs) in cancer progression and therapy. J Cell
Physiol. 234:8381–8395. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Fu X, Wu S, Li B, Xu Y and Liu J:
Functions of p53 in pluripotent stem cells. Protein Cell. 11:71–78.
2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cao X, Hou J, An Q, Assaraf YG and Wang X:
Towards the overcoming of anticancer drug resistance mediated by
p53 mutations. Drug Resist Updat. 49(100671)2019.PubMed/NCBI View Article : Google Scholar
|
